BioSpace News Archive

Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the acceptance of its Clinical Trial Application (CTA) from the National Agency for the Safety of Medicines and Health Products (ANSM) in France to allow initiation of its Phase 1/2 clinical trial of INZ-701,

Soligenix, Inc. announced that it has received approximately $865,000, net of transaction costs, in non-dilutive financing via the state of New Jersey’s Technology Business Tax Certificate Transfer Program.

China Pharma Holdings, Inc., a specialty pharmaceutical company, announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale test.

ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the closing of a $45 million financing tranche that brings the total Series D financing to more than $115 million.